Infectious disease specialists W. David Hardy, MD, AAHIVS, and David Alain Wohl, MD, explore ways to optimize therapy selections and switch strategies in the treatment of persons living with HIV infection (PLWH), including considerations for treating PLWH in a pandemic landscape. Topics include current and ongoing disparities in HIV treatment, with strategies to overcome them, an introduction to the rapid initiation of antiretroviral therapy (ART), clinical trial data on the use of 2- and 3-drug ART regimens, an exploration of the uses of long-acting injectable ART, the use of shared decision-making to engage PLWH in treatment decisions, and suggestions on how to optimize treatment outcomes for PLWH. Case studies are discussed to examine how to apply these principles to common clinical scenarios, including overcoming pill fatigue and addressing barriers in treatment-naïve individuals.
Course Credit:
2.00 AMA PRA Category 1 CreditsTM
Dates:
Opens: 2021-11-19
Closes: 2022-11-19
Target Audience:
A national audience of HIV specialists and infectious disease specialists, plus other physicians with an interest in HIV care, including primary care physicians and emergency medicine physicians.
This educational activity is supported by an independent educational grant from ViiV Healthcare.
-
W. David Hardy, MD, AAHIVS
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California -
David Alain Wohl, MD
Professor of Medicine
Division of Infectious Diseases
Site Leader, HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill
University of North Carolina School of Medicine
Co-Lead, UNC Viral Hemorrhagic Fever Research Working Group